Vetigenics was founded in 2017 through a National Cancer Institute (NCI) small business innovation research award to create fully canine research antibodies to support the field of comparative oncology. The company’s mission has evolved to transform personalized healthcare for pets while driving advancements in human medicine. Our state-of-the-art phage display platform enables us to rapidly produce entirely canine antibodies or CANIBODIES™ that are the building blocks for monoclonal and bispecific antibodies, CAR T-cells, and more. Our novel technology has successfully generated antibodies for both dogs and cats across a wide range of therapeutic areas. Vetigenics remains committed to the field of comparative oncology and has created a path to enable pets and their humans to live their best lives.
Vetigenics’ proprietary CANIBODY™ Platform is an entirely canine phage display library containing over 40 billion naturally occurring canine antibodies. Our unique screening techniques isolate superior antibodies against any target antigen, without immunizations or animal sacrifice, making it faster, more cost-effective and ethical, for multiple therapeutic and research applications.
Revolutionary Therapies for Managing
Chronic Diseases in Pets
Stay connected and informed with our latest news and insights
Our pipeline is designed to address unmet needs across multiple therapeutic areas
Partners for Pet Health
Partners can rely on us to rapidly generate novel therapies and research tools
Learn how pet dogs can accelerate new treatments for themselves and their humans